NOVO HOLDINGS A S
Q4 2025 Form 13-F
HELLERUP, DENMARK
CIK 0001388325
· Institutional investment manager
$1.3B Reported Value Total
Reported value
$1.3B
Quarter over quarter
+14.3%
Holdings
24
Top-10 concentration
71.3%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Barbara Fiorini
General Counsel
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 24 |
| Change in reported value | -17.0% |
| New positions | 1 |
| Exited positions | 4 |
| Position turnover | 17.9% |
| Top-10 concentration | 71.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
25 | $1.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
22 | $1.2B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
24 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
27 | $1.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $1.4B |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
34 | $1.7B |
|
Q3 2024 13F
Filed Oct 24, 2024
|
37 | $2.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
38 | $1.9B |
|
Q1 2024 13F
Filed May 15, 2024
|
35 | $1.4B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
36 | $1.6B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
40 | $1.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
41 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
47 | $1.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
48 | $1.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
52 | $2.1B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
54 | $2.0B |
|
Q1 2022 13F
Filed May 16, 2022
|
51 | $1.9B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
48 | $2.1B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
49 | $1.9B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BN BROOKFIELD CORP | $160.4M | 12.46% |
| 2 | EWTX EDGEWISE THERAPEUTICS INC | $132.8M | 10.31% |
| 3 | ASML ASML HOLDING N V | $121.9M | 9.47% |
| 4 | MIRM MIRUM PHARMACEUTICALS INC | $99.8M | 7.75% |
| 5 | CRM SALESFORCE INC | $87.5M | 6.79% |
| 6 | CRNX CRINETICS PHARMACEUTICALS IN | $75.6M | 5.87% |
| 7 | VRDN VIRIDIAN THERAPEUTICS INC | $74.1M | 5.75% |
| 8 | MPLT MAPLIGHT THERAPEUTICS INC | $64.8M | 5.03% |
| 9 | ZBIO ZENAS BIOPHARMA INC | $52.6M | 4.09% |
| 10 | PHVS PHARVARIS N V | $48.6M | 3.77% |
| 11 | APGE APOGEE THERAPEUTICS INC | $43.0M | 3.34% |
| 12 | PCVX VAXCYTE INC | $42.3M | 3.28% |
| 13 | BMRN BIOMARIN PHARMACEUTICAL INC | $39.2M | 3.05% |
| 14 | AVBP ARRIVENT BIOPHARMA INC | $39.1M | 3.03% |
| 15 | BABA ALIBABA GROUP HLDG LTD | $37.7M | 2.93% |
| 16 | INSM INSMED INC | $34.8M | 2.7% |
| 17 | CLDX CELLDEX THERAPEUTICS INC NEW | $32.6M | 2.53% |
| 18 | FDMT 4D MOLECULAR THERAPEUTICS IN | $27.4M | 2.13% |
| 19 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | $24.6M | 1.91% |
| 20 | ELVN ENLIVEN THERAPEUTICS INC | $22.8M | 1.77% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.